Since Operations Iraqi Freedom and Enduring Freedom began, many American servicemen and women have been infected with antibiotic-resistant bacteria.¹ While our men and women in uniform increasingly survive severe wounds sustained in combat, their injuries leave them susceptible to life-threatening, hard-to-treat infections. Marine Lance Corporal Jonathan Gadsden’s story reflects the growing need for new antibiotics that can treat these dangerous diseases, against which most drugs are useless.
Twenty-year-old Marine Lance Corporal Jonathan Gadsden was seriously wounded on August 21, 2004, after a homemade bomb exploded under his Humvee in Anbar Province, Iraq.²
Cpl. Gadsden was treated on the scene by combat medics and then airlifted to a military hospital in a former health care facility in Baghdad. Surgeons repaired wounds to his cranium, removed his spleen, and administered powerful antibiotics to ward off potential infections. Once stable, Cpl. Gadsden was transferred to an American military hospital in Germany and then to the National Naval Medical Center in Maryland, where he tested positive for a variety of pathogens, including Acinetobacter baumannii, Staphylococcus, Pseudomonas, Klebsiella, and Enterobacter — most of which are commonly multidrug-resistant.
By September, he seemed to be on the road to recovery. Cpl. Gadsden was able to breathe without a ventilator and move about with a walker. When he was transferred to the James A. Haley Veterans’ Hospital in Florida, his new doctors told his mother, Zeada Gadsden, that her son might be able to return home to South Carolina by the end of October.
But in early October, after finishing his prescribed course of antibiotics, Cpl. Gadsden began to exhibit symptoms as if an infection was present. When testing showed he had a urinary tract infection, doctors administered more antibiotics. His condition initially improved, but by October 17 he began to deteriorate.
Three days later, he had a seizure and went into cardiac arrest. Even though Cpl. Gadsden was given a number of antibiotics—at least four different classes—they proved insufficient. He died on October 22, 2004.
Cpl. Gadsden’s death demonstrates the great and growing threat of infections that are difficult, and sometimes impossible, to treat, complicating the care of our combat-injured military personnel.³
Mrs. Gadsden laments that the doctors ran out of options to treat her son’s illness. “If so many guys are suffering from multidrug-resistant infections, then we need to come up with something,” she said.
- Date added:
- Aug 16, 2012
2. J. D. Daigh, "Healthcare Inspection: Review of Quality of Care, Department of Veterans Affairs, James A. Haley Medical Center,Tampa, Florida," ed. Department of Veterans Affairs Office of Inspector General (Washington, DC 2005).
3. D. R. Hospenthal et al., "Multidrug-resistant bacterial colonization of combat-injured personnel at admission to medical centers after evacuation from Afghanistan and Iraq," Journal of Trauma a nd Acute Care Surgery 71, no. 1 Suppl (2011).
On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.More info
Last spring, Arjun Srinivasan, an associate director of the CDC, delivered a presentation to state health officials with some alarming information. Before the year 2000, he said, it was rare to find cases of bacteria resistant to carbapenems, a class of powerful, last-resort antibiotics. But by February 2013 they had been seen in almost every state. On March 5, Thomas Frieden, director of the CDC, issued a public warning about “nightmare” bacteria, a family of germs known as CREs. They can kill up to half the patients who get bloodstream infections from them, resist most or all antibiotics and spread resistance to other strains.More info
"On Sept 16, the US Centers for Disease Control and Prevention (CDC) released its report Antibiotic Resistance Threats in the United States, 2013 —their first ever reporton this subject. From the outset the tone is clear: in his foreword, Tom Frieden, director of the CDC, states that "antimicrobial resistance is one of our most serious health threats. Infections from resistant bacteria are now too common." The stated aim of this report is to increase awareness of the threat resistance poses and to encourage immediat e action to address this threat."More info
"A recent report from the Centers for Disease Control and Prevention is adding urgency to an issue lawmakers from both parties say they want to address: the rise of bacteria that are resistant to antibiotics."More info